YourBio Health Delivers Superior Method for At-home Serum Anti-Mullerian Hormone Testing
BOSTON, Nov. 2, 2022 /PRNewswire/ -- YourBio Health, Inc., and Turtle Health, Inc., today announced that the TAP® II device, when utilized as part of Turtle Health's lab-developed home test, can reliably produce similar results to in-clinic venipuncture, according to a trial published in Reproductive Biology and Endocrinology. The study, conducted in 41 women of reproductive age and sponsored by Turtle Health, compared three modes of blood collection: the TAP II device self-administered by the patient with Turtle Health instructions and packaging, the ADx card, self-administered by the patient with ADx manufacturer instructions, and venipuncture as conducted by a qualified phlebotomist.
- TAP II Device delivers superior correlation and fewer false positives versus the DBS ADx 100 card and a significantly preferred experience to venipuncture.
- Patients significantly preferred the TAP II device with statistically superior patient experience, as measured by Net Promoter Score (NPS) versus both the ADx card and venipuncture.
- In addition to producing superior results to the ADx card, we can deliver better health data across more patients."
- Learn more at www.yourbiohealth.com
YourBio Health was founded by Flagship Pioneering, which conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.